Skip to main content
. 2022 Oct 28;38(1):118–137. doi: 10.1080/14756366.2022.2136172

Figure 5.

Figure 5.

Graphical representation for half-maximal inhibitory concentration (IC50) of the target compounds and doxorubicin after treatment for 24 h on the prostate cancer cell line.